hrcak mascot   Srce   HID



MIRO MOROVIĆ ; Zadar General Hospital, Department of Infectology, Zadar, Croatia
IRENA HRSTIĆ ; Pula General Hospital, Department of Internal Medicine, Division of Gastroenterology, Pula, Croatia

Fulltext: croatian, pdf (100 KB) pages 319-323 downloads: 2.105* cite
APA 6th Edition
MOROVIĆ, M. & HRSTIĆ, I. (2013). LIJEČENJE KRONIČNOG HEPATITISA B. Acta medica Croatica, 67 (4), 319-323. Retrieved from
MLA 8th Edition
MOROVIĆ, MIRO and IRENA HRSTIĆ. "LIJEČENJE KRONIČNOG HEPATITISA B." Acta medica Croatica, vol. 67, no. 4, 2013, pp. 319-323. Accessed 20 Sep. 2021.
Chicago 17th Edition
MOROVIĆ, MIRO and IRENA HRSTIĆ. "LIJEČENJE KRONIČNOG HEPATITISA B." Acta medica Croatica 67, no. 4 (2013): 319-323.
MOROVIĆ, M., and HRSTIĆ, I. (2013). 'LIJEČENJE KRONIČNOG HEPATITISA B', Acta medica Croatica, 67(4), pp. 319-323. Available at: (Accessed 20 September 2021)
MOROVIĆ M, HRSTIĆ I. LIJEČENJE KRONIČNOG HEPATITISA B. Acta medica Croatica [Internet]. 2013 [cited 2021 September 20];67(4):319-323. Available from:
M. MOROVIĆ and I. HRSTIĆ, "LIJEČENJE KRONIČNOG HEPATITISA B", Acta medica Croatica, vol.67, no. 4, pp. 319-323, 2013. [Online]. Available: [Accessed: 20 September 2021]

Clinical practice guidelines for the management of chronic hepatitis B infection continue to evolve from year to year but the goal remains the same, i.e. long-term continued suppression of viral replication to prevent disease progression and development of cirrhosis and hepatocellular carcinoma. Out of seven drugs approved for the treatment of chronic hepatitis B, current guidelines recommend entecavir and tenofovir from the nucleos(t)ide analogues and pegylated interferon alfa-2a for the selected group of patients as first-line monotherapies. Both groups showed good results in a number of clinical trials and are used according to the consensus criteria. The treatment of special populations with chronic HBV infection, i.e. those with HCV/HDV/HIV co-infections, immunocompromised patients, patients who have undergone transplantation, patients with solid tumor and cirrhosis, patients with chronic renal failure on dialysis, pregnant women and children, is more often required and more demanding than for usual chronic hepatitis B.

hepatitis B; nucleos(t)ide analogues; pegylated interferon; therapy

Hrčak ID: 113718



Visits: 2.426 *